Table 2.
Demographic and clinical characteristics of the Pharmachild patients with infections
| Data aren(%) or medians with IQR range | Patients adjudicated* (N = 572) | Patients not adjudicated* (N = 323) | Patients with infections (N = 895) | P(patients adjudicated vs not adjudicated) | |
|---|---|---|---|---|---|
| Females | 388 (67.8%) | 241 (74.6%) | 629 (70.3%) | 0.033 | |
| Age at onset | 3.1 (1.7–6.7) | 4.1 (2.1–8.5) | 3.5 (1.9–7.3) | 0.001 | |
| Age at JIA diagnosis | 3.7 (2.1–7.5) | 4.9 (2.4–9.5) | 4.1 (2.2–8.1) | 0.001 | |
| Disease duration at last FU | 7.6 (5.0–11.1) | 5.8 (3.1–10.3) | 7.1 (4.2–10.8) | < 0.001 | |
| JIA category | 0.004 | ||||
| Systemic | 120 (20.9%) | 37 (11.4%) | 157 (17.5%) | ||
| Oligo persistent | 101 (17.7%) | 80 (24.8%) | 181 (20.2%) | ||
| Oligo extended | 100 (17.5%) | 50 (15.5%) | 150 (16.8%) | ||
| Polyarticular RF- | 132 (23.1%) | 84 (26.0%) | 216 (24.1%) | ||
| Polyarticular RF+ | 19 (3.3%) | 15 (4.6%) | 34 (3.8%) | ||
| Psoriatic | 25 (4.4%) | 8 (2.5%) | 33 (3.7%) | ||
| Enthesitis | 36 (6.3%) | 21 (6.5%) | 57 (6.4%) | ||
| Undifferentiated | 39 (6.8%) | 28 (8.7%) | 67 (7.5%) | ||
| Systemic glucocorticoids | 336 (58.7%) | 154 (47.7%) | 490 (54.7) | 0.001 | |
| Synthetic DMARDs | |||||
| Methotrexate | 532 (93.0%) | 289 (89.5%) | 821 (91.7%) |
0.065 < 0.001 |
|
| Cyclosporine | 90 (15.7%) | 13 (4.1%) | 103 (11.5%) | < 0.001 | |
| Sulfasalazine | 66 (11.5%) | 28 (8.7%) | 94 (10.5%) | 0.179 | |
| Leflunomide | 40 (7.0%) | 28 (8.7%) | 68 (7.6%) | 0.364 | |
| Azathioprine | 17 (3.0%) | 6 (1.9%) | 23 (2.6%) | 0.312 | |
| Hydroxychloroquine | 14 (2.4%) | 9 (2.8%) | 23 (2.6%) | 0.758 | |
| Thalidomide | 7 (1.2%) | 2 (0.6%) | 9 (1.0%) | 0.501 | |
| Biologic DMARDs | |||||
| Etanercept | 298 (52.1%) | 126 (39.0%) | 424 (47.4%) | < 0.001 | |
| Adalimumab | 178 (31.1%) | 82 (25.4%) | 260 (29.1%) | 0.070 | |
| Tocilizumab | 103 (18.0%) | 19 (5.9%) | 122 (13.6%) | < 0.001 | |
| Infliximab | 84 (14.7%) | 17 (5.3%) | 101 (11.3%) | < 0.001 | |
| Anakinra | 54 (9.4%) | 28 (8.7%) | 82 (9.2%) | 0.701 | |
| Abatacept | 39 (6.8%) | 17 (5.3%) | 56 (6.3%) | 0.356 | |
| Canakinumab | 28 (4.9%) | 10 (3.1%) | 38 (4.2%) | 0.200 | |
| Rituximab | 26 (4.5%) | 3 (0.9%) | 29 (3.2%) | 0.003 | |
| Golimumab | 14 (2.4%) | 6 (1.9%) | 20 (2.2%) | 0.566 | |
| Certolizumab | 4 (0.7%) | 1 (0.3%) | 5 (0.6%) | 0.453 | |
| Other biologic agents | 2 (0.3%) | 1 (0.3%) | 3 (0.3%) | 1.000 | |
Data are n (%) or medians with IQR range. Drugs refer to their administration at any time during the patient’s history and are sorted by their descending frequencies. *The adjudicated patients are represented by those with opportunistic infections as per the provisional list of opportunistic pathogens/presentations (step 1), and very severe/severe or serious non-opportunistic infections. The remaining ones represent the not adjudicated patients. JIA juvenile idiopathic arthritis, FU follow-up, RF rheumatoid factor, DMARDs disease-modifying anti-rheumatic drugs